Results: Analyses of key safety outcomes from NOAC trials were completed using primary trial data, including major bleeding and all-cause mortality. The safety of NOACs was generally consistent and favourable compared with warfarin according to patient age, gender, previous history of stroke, and the presence of risk factors for stroke.
| INTRODUC TI ON
Atrial fibrillation (AF) is associated with an increased risk of morbidity and mortality, in part as a result of an increased risk of stroke in this population.
1,2 AF increases the risk of stroke fivefold compared with the general population. 1 Accordingly, lifelong anticoagulation therapy is recommended for patients with AF. 3 Typically, this has involved the use of vitamin K antagonists, primarily warfarin. 4 Wellcontrolled warfarin therapy has been shown to be highly effective in the prevention of stroke in patients with AF and is associated with a relative risk reduction in 64% compared with control/placebo, as well as a 26% reduction in all cause mortality. 5 However, achieving well-controlled warfarin therapy in practice is a demanding process. 6, 7 Warfarin has a narrow therapeutic range, defined as an international normalised ratio (INR) of 2.0-3.0 and this time in therapeutic range (TTR) should be achieved for >70% of the treatment period to ensure optimal outcomes. 7 When the INR is too low, the risk of stroke increases, while an elevated INR increases the risk of bleeding. 8, 9 Maintaining the INR within this range is complicated by the multiple drug and food interactions observed with warfarin therapy, as well as significant intra-and inter-individual variability in the pharmacological profile of the drug and the healthcare system in which a service operates. 6, 7 Multiple commonly occurring risk factors have been defined and prospectively validated, predicting a failure to achieve TTR. 10 The risk of bleeding on warfarin therapy is one of the most significant concerns of patients and physicians, because of the morbidity and mortality associated with major bleeding events. 7, 11 Therefore, anticoagulation therapy with the non-vitamin K oral anticoagulants (NOACs), which do not require routine anticoagulant monitoring and have a more predictable 
R E V I E W A R T I C L E
The safety of NOACs in atrial fibrillation patient subgroups: A narrative review pharmacological profile, may be practically advantageous and more acceptable to patients compared with warfarin therapy.
Four NOACs are licensed for use in patients with non-valvular AF in the United States and Europe: apixaban, dabigatran, edoxaban, and rivaroxaban. Evidence from phase III trials suggests that the NOACs have a favourable efficacy and safety profile compared with warfarin. 12 Whilst there have not be direct comparisons with antiplatelet drugs or placebo (apart from apixaban 13 ), indirect comparisons clearly show superior efficacy and the safety of NOACs vs antiplatelet drugs or placebo. 14 However, it is recognised that the efficacy and safety profiles of anticoagulant therapy are not homogeneous in the AF population.
Different patient risk factors may contribute towards an increased risk of stroke or bleeding. 15 It is important that these risk factors are identified and factored into clinical decision-making, as the risk of bleeding complications remains a significant reason for avoiding anticoagulation therapy in eligible patients. 16, 17 Bleeding risk factors have been identified by multiple bleeding risk scoring schemes, including the HAS-BLED score 18 which allows for identification of modifiable risk factors prior to initiation of anticoagulation therapy and to "flag up" those at high bleeding risk for early review and follow-up (eg, 4 weeks rather than 4-6 months). 19 Clarifying the relative safety profiles of the NOACs compared with warfarin and other the other agents from the NOAC class in individual patient populations will be vital in promoting the appropriate use of anticoagulant therapy in the future.
Despite the available data supporting the use of NOACs as an alternative to warfarin in patients with AF, there are significant gaps in the knowledge base. Of particular concern is the lack of data that allow physicians to differentiate between specific NOACs based on individual patient characteristics. 20 Certain patient subgroups may be associated with different relative risks of stroke and/or bleeding with anticoagulation. 21 Both the American College of Chest Physicians (ACCP) 22 and the National Institute for Health and Care
Excellence (NICE) 23 in the UK suggest the need for tailored NOAC recommendations to reflect the differences in efficacy and safety of each NOAC in different patient risk profiles, and consideration of patient choice.
Determining the most appropriate NOAC for these subgroups requires a careful assessment of the net clinical benefit of each agent in the context of patient-specific factors. 24 However, head-to-head trials of the NOACs are non-existent, disempowering physicians aiming to tailor therapy to the needs of the patient. The recent 2018 ACCP guidelines also makes suggestions for particular OAC drugs to fit the patient clinical profile, based on subgroup data from trials and real world postmarketing observational evidence. 25 The use of NOACs in the management of valvular AF is controversial, and warfarin use persists in this diverse population.
However, evaluation of clinical trial data 26 suggests that NOACs may be an alternative to warfarin in patients with AF and native aortic valve disease, tricuspid valve disease, or mitral regurgitation, and a CHA 2 DS 2 -VASc score of 2 or greater, leading to incorporation of these indications in recent guidelines for valvular heart disease. 27 A recent consensus guideline notes that the term "valvular AF" is obsolete, and should be replaced by the term "AF with valvular heart disease", further categorised into Evaluated 
| ME THODOLOGY
This review examined data pertaining to four NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) evaluated in phase III trials, assessing the favourability of agents in specific patient subgroups for the treatment of AF, using pooled analyses where appropriate.
Study-specific event rates among patient subgroups were pooled using a fixed effects meta-analysis model. Statistical heterogeneity across the trials was found to be minimal, as assessed using the I 2 statistic. In the absence of reported effect estimates, risk ratios were calculated from raw data in every available trial.
| THE PHA S E III NOAC TRIAL S , AND B E YO N D
Four main NOAC trials have been conducted in the context of the management of AF. Overall, the NOAC trials demonstrate that
Review criteria
• A comprehensive literature search was completed using online databases.
• Primary study data were extracted and analysed.
Message for the clinic
• NOACs generally have a favourable safety profile to warfarin in all patient subgroups.
• Some NOACs may have better safety profiles than others based on indirect analyses.
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each agent is at least non-inferior to warfarin for the prevention of stroke/systemic embolic events (SEE) and with respect to bleeding safety endpoints, compared with warfarin therapy. 13, [29] [30] [31] Results of the NOAC trials are summarised in Table 1 . Although these trials are similar in many respects, there are important differences in trial design, study participants and outcome measures that should be considered, and have been the subject of numerous reviews. 39 Similarly, a recent network metaanalysis found that all NOACs were superior to aspirin or placebo for stroke prevention, while aspirin, apixaban, dabigatran 110 mg, and edoxaban were associated with less major bleeding than warfarin. 40 Dabigatran has also been shown to have benefits for the prevention of stroke/SEE and mortality over antiplatelets and placebo, based on indirect evidence, without an indication of increased risk of ICH. well as comparative effectiveness of the NOACs against each other.
The numbers of papers have largely reflected the sequence these drugs have been approved and licensed for clinical use.
For the comparisons of NOACs vs warfarin, various studies have reported the effectiveness and safety of dabigatran compared to warfarin [42] [43] [44] that have been summarised in a systematic review and meta-analysis. 45 The latter shows that dabigatran was associated with a lower risk of ischaemic stroke than VKA therapy as well as a For rivaroxaban, real world data such as the XANTUS study 46 show that the rates of stroke and major bleeding are low in patients 49 The findings suggested that apixaban and VKA therapy had a similar impact on this endpoint.
Two recent real-world evaluations of edoxaban vs warfarin therapy have been published, and show that edoxaban is likely to be associated with a reduced risk of ischaemic stroke, major haemorrhage, and all-cause death compared with warfarin, even in high-risk subgroups 50 and for both doses of edoxaban, although low-dose edoxaban (30/15 mg) had lower effectiveness for the prevention of stroke compared with warfarin where creatinine clearance was above 95 mL/min, suggesting that the higher dose regimen (60/30 mg) should be used in this group to maintain efficacy, while preserving safety. 51 Comparative effectiveness and safety studies have been published between the NOACs and warfarin. The REVISIT-US study 52 evaluated real-world effectiveness and safety of apixaban or rivaroxaban vs warfarin and found that both drugs were associated with a reduction in the combined endpoint of stroke or intracranial haemorrhage compared with warfarin. However, ischaemic stroke was non-significantly increased with apixaban vs warfarin (HR, 1.13; 95% CI, 0.49-2.63), but small numbers and the short follow-up preclude over-interpretation of these data. A real-world analysis of claims databases in the United States found no difference in the risk of stroke/SEE between apixaban, dabigatran, and rivaroxaban. 53 Apixaban was associated with a lower risk of major bleeding than dabigatran or rivaroxaban, while rivaroxaban was associated with an increased risk of major bleeding and intracranial bleeding compared with dabigatran.
Yao et al 54 found that apixaban was associated with lower risks of stroke/SEE and major bleeding compared with warfarin, while stroke/SEE risk was similar between warfarin, dabigatran, and rivaroxaban and major bleeding was lower with dabigatran. It has also been shown that among newly anticoagulated patients, apixaban, and dabigatran were associated with a lower risk of major bleeding compared with warfarin initiation, while rivaroxaban was associated with a higher risk of major bleeding compared with apixaban. 55 An analysis of 118 891 patients also found that rivaroxaban treatment was associated with an increased risk of intracranial haemorrhage and major extracranial bleeding, including major gastrointestinal bleeding, compared with dabigatran treatment. 56 
| HI G H -RIS K PATIENT SUBG ROUPS FROM THE RC TS
The remainder of this paper will focus on four key patient subgroups that are of particular importance when considering anticoagulation therapy in patients with AF. These subgroups are: elderly patients, women patients, patients with a high number of stroke risk factors, and patients with previous stroke. For each subgroup, a detailed examination of the available literature is provided, accompanied by a novel analysis of raw trial data, aimed at supplementing available knowledge on the safety of NOACs for each subgroup.
| Age
Patient age is considered as one of the major risk factors for stroke and bleeding in the context of anticoagulation therapy for AF. 57 The majority of patients with AF are aged over 60 years, with approximately one-third ≥75 years old. 58 It is estimated that at least 10% of patients over the age of 75 years have AF. 59 The risk of major bleeding increases with age in patients with AF, particularly when receiving anticoagulation therapy. 60, 61 An increased risk of stroke has been related to underuse of anticoagulation in the elderly people's population, with one study demonstrating 75% of AF patients aged <75 years receiving anticoagulation following a stroke compared with 33% of patients aged >85 years, based on hospital admission records. 62 Furthermore, one study has found that rates of warfarin prescription declined with increasing age on hospital discharge and that age was the single greatest reason cited for non-prescription of warfarin in the elderly people. 63 This is despite the finding that the clinical benefit of anticoagulation is the greatest in the most elderly patients (>85 years old). 64 This is a worrying phenomenon, suggesting under-treatment of patients with AF, particularly as the relative benefits of anticoagulation tend to outweigh the potential negative effects, regardless of age. 12 Analyses of phase III trials have suggested that the efficacy and safety of the NOACs remain favourable compared with warfarin, even in patients aged ≥75 years old (Table 2 ). In the subgroup The selection of NOACs based on patient age is a complex process and care must be taken to ensure that the comorbidities associated with increased age are considered during this decision-making process. Hypertension, congestive heart failure, type 2 diabetes and previous stroke are all risk factors for future stroke and bleeding risk and are more common in the elderly people population than in younger patients. 69 Similarly, renal function declines with age 70 and polypharmacy increases with age 71 ; both may influence the effectiveness and safety of NOAC therapy. 72 Therefore, basing the selection of NOACs on age alone may be inappropriate, unless these other factors are also considered. Dose-reduced regimens of NOACs may also be justified based on patient age, in combination with other factors (ie, body weight, concomitant medication, and renal function). 
| Gender
Compared with men, women develop AF at an older age [74] [75] [76] and have a higher risk of stroke. 77 Being women affords an increased risk of stroke, which is reflected in the CHA 2 DS 2 -VASc score and women gender is also a risk factor for maintaining time in the therapeutic range of warfarin therapy, reflected in the SAMe-TT 2 R 2 score. 10 Even when women spend a significant amount of time within the therapeutic range (>66%) their risk of stroke is higher than for men. 78 Whilst women have an increased stroke risk compared with men, there is no significant difference in composite cardiovascular death and stroke/SEE. 79 The reasons underlying the increased risk of stroke in women with AF are unclear, although an increased rate of hypertension 80 and structural differences in the left atrium compared with men, 81 have been proposed to account for some of this increased risk. Regardless of the underlying reasons, the efficacy and safety of NOACs in women with AF remains uncertain at present.
A meta-analysis of NOACs vs warfarin showed that women with AF have a greater risk of cerebrovascular events and systemic embolism compared with men, but that these differences are not seen when both sexes are treated with NOACs (apixaban, dabigatran, or rivaroxaban). 82 This meta-analysis also found that women had a lower risk of major bleeding then men on NOAC therapy (OR, 0.849, CI, 0.745-0.955, P = 0.007). An indirect comparison of NOAC therapy in women suggested that there were no differences in the safety and efficacy of NOACs in this population. 83 Our analysis of data extracted from phase III NOAC trials in patients with AF was used to explore the effect of gender on a single key safety outcome: major bleeding (Figure 2 ). Data were only available for absolute patient numbers from the RE-LY, ARISTOTLE, and ROCKET-AF trials, while data on all-cause mortality were not available for all studies according to patient gender. The results of this analysis suggest that there is little difference in the rates of major bleeding with individual NOACs when comparing male and female patients. In both male and female patients the NOACs collectively showed statistically favourable results compared with warfarin therapy. Apixaban may be associated with a more pronounced reduction in major bleeding vs warfarin therapy in women compared with men.
Therefore, the available evidence suggests that safety outcomes for men and women are similar, with a reduction in major bleeding compared with warfarin therapy, regardless of the individual NOAC used. Therefore, no specific agent may be preferred based on patient gender alone. Data on edoxaban suggest that outcomes in men and women are very similar, 30 but pending a more robust analysis of data on edoxaban, and head-to-head trials comparing the safety of NOACs, NOAC selection in both men and women should be based on patient preference and clinical characteristics (eg, renal function, bleeding risk factors).
| ACCUMUL ATED RIS K FAC TOR S FOR S TROK E
As noted above, there are multiple risk factors for stroke that are of particular relevance in patients with AF. The CHA 2 DS 2 -VASc stroke should be used to (strongly) recommend oral anticoagulant therapy whilst for one stroke risk factor ie, CHA 2 DS 2 -VASc score of one for men and two for women, OAC "should be considered". 88 The latter reflects the lack of RCTs specifically studying patients with one stroke risk factor 89, 90 . However, stroke rates vary depending on the risk factor that is present. 64 One analysis from a National Primary
Care Database found that the stroke rate was highest when advanced age or previous stroke was present, compared with other risk factors. 91 Therefore, it remains challenging to accurately stratify patients according to stroke risk based on the use of standardised risk scoring; the impact of individual risk factors appears to be important in AF patients on the borderline of the treatment threshold. 92 The 2018 ACCP guidelines recommend a stepwise approach, to initially identify low risk patients (CHA 2 DS 2 VASc 0 in men or one in women), for whom no antithrombotic therapy is recommended; the next step is to offer stroke prevention (ie, oral anticoagulants)
to those with ≥1 stroke risk factors. 25 This reflects that the default strategy should be to offer stroke prevention unless the patient is low-risk.
The phase III NOAC trials utilised CHADS 2 scores to calculate patient risk of stroke and to stratify patient subgroups, hence the CHADS 2 score is used in analyses of data from these trials. It should be noted that the ENGAGE AF-TIMI 48 trial used a CHADS 2 score ≥2
as an inclusion criterion for patients in both the edoxaban and warfarin treatment groups. As a result, it is not possible to compare the safety of edoxaban in patients with CHADS 2 <2 with those achieving higher scores, based on phase III trial data.
Data extracted from phase III trials indicated that all NOACs were associated with a reduction in major bleeding compared with warfarin, regardless of the CHADS 2 score (Figure 3 ). This effect was statistically significant only in patients with CHADS 2 scores of 2 or more (P < 0.001), indicating that NOACs may be more favourable than warfarin in preventing major bleeding in patients at a greater risk of stroke. This effect was less pronounced for all-cause mortality (Figure 4 ), although the NOACs remained favourable compared with warfarin therapy, although this was not statistically significant.
Furthermore data on apixaban suggested that patients with CHADS 2 >3 showed the greatest reduction in stroke, with better efficacy and safety than in patients with lower CHADS 2 scores. 93 In the RE-LY study, the greatest absolute risk reduction in stroke is seen in patients with the highest risk of stroke or bleeding treated with dabigatran vs warfarin. 
RR (95% CI)
| PRIMARY VS S ECONDARY S TROK E PRE VENTI ON
The phase III NOAC trials generally found that patients with previous stroke/transient ischaemic attack (TIA) had a higher rate of stroke than patients without a history of stroke/TIA. The enrolment rates of patients with previous stroke/TIA did vary between phase III trials, however, with ROCKET-AF showing the highest rate of patients with previous stroke/TIA (55% Phase III trial data were analysed in order to explore the relative safety of NOACs based on the use of NOACs for primary vs secondary stroke prevention in the AF population ( Figures 5 and 6 ). The findings showed that the NOACs were favourable compared with warfarin in both primary and secondary stroke prevention contexts, when the outcome of major bleeding was considered (P < 0.001 for both primary and secondary populations; Figure 5 ). The strongest benefits were apparent with apixaban and edoxaban, while the rate of major bleeding with rivaroxaban, in particular, was less favourable compared with warfarin in the primary prevention context.
When all-cause mortality was considered as a key safety outcome, the NOACs performed similarly and were favourable compared with warfarin for both primary and secondary stroke prevention populations, although these effects did not reach statistical significance ( Figure 6 ).
In summary, the NOACs appear to be associated with a lower rate of major bleeding than warfarin in patients receiving anticoagulation for primary or secondary stroke prevention, with the exception of rivaroxaban. Edoxaban and apixaban had particularly favourable safety outcomes in both patient populations. 103, 104 Warfarin use in Asian patients with AF is associated with higher rates of stroke than that seen in nonAsians. 103 The use of NOACs in the Asian population has been shown to reduce the risk of stroke and does not lead to increased bleeding events compared with warfarin therapy, based on Phase III trial data. 105 Similarly, real-world data suggest that the risk of ischaemic stroke is similar with NOACs and warfarin use in Asian patients, while the risk of ICH is lower with NOACs. 106 One of the perceived advantages of warfarin therapy is the ability to monitor the anticoagulation effect through INR levels, which provides reassurance to clinicians that effective anticoagulation is achieved and maintained. Uncertainty over the "true" anticoagulant effects of NOACs, based on specific plasma markers, may lead to doubt over the achievement of effective anticoagulation among clinicians. 107 However, as NOACs achieve a more predictable anticoagulant effect than warfarin, plasma level monitoring of NOACs is not recommended on a routine basis. Indeed, plasma levels may not be indicative of anticoagulant effect and limited data support this strategy. 101 Therefore, there is no clear place for monitoring plasma levels of NOACs to maximise benefits or minimise risks in routine practice at present.
| ADDITIONAL SAFE T Y CONS IDER ATIONS
Despite the many advantages of NOACs compared with VKA therapy, careful decision-making is required to ensure the safety of selecting on option over another. As more data emerge from clinical trials and real-world analyses, the use of NOACs is becoming more diverse, replacing VKA therapy in many contexts as a safe, reliable, and effective treatment approach. 108 VKA therapy still has a role to play in many contexts, including situations where NOACs are contraindicated (eg, renal failure). However, uncertainty over the relative efficacy of different NOACs and clinical inertia often accounts for the preference for VKA therapy in clinical practice 109 and this must be addressed through careful examination of NOAC safety and clarity in clinical guidelines to ensure patient safety and the effectiveness of anticoagulation.
| LI M ITATI O N S
All of the analyses presented in this manuscript are based on indirect comparisons of NOAC patient subgroups, which have inherent limitations compared with analyses based on head-to-head trials. 
| CON CLUS ION
This review highlights the importance of considering patient subgroups and specific stroke risk factors when initiating antithrombotic therapy in patients with AF. The safety of the NOACs compared with warfarin was generally favourable across different patient subgroups.
However, certain NOACs may be preferable to warfarin in some subgroups, based on indirect analyses. It will be important to confirm these findings in head-to-head trials in order to effect changes in clinical practice consistent with optimisation of patient safety.
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